{# Audit 04/10/2026 : « autre » n'est pas un code de langue ; SPHAERO n'est pas l'éditeur des documents qu'elle héberge ou référence. #} {# citation_pdf_url doit mener à un PDF : un lien vers une page DOI est pénalisé par Google Scholar (avant : tout lien externe). #}
Accès ouvert · CC BY

Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions

Article scientifique 2025 Anglais

Résumé

Cancer research is constantly evolving to yield successful innovations. A plethora of pre-clinical studies have illustrated the promising potential utility of parasites and parasite-derived molecules in cancer therapy. In this review, we underscore, for the first time, the possible multifaceted applications of parasites in the field of oncology, aiming to draw attention to the vital role of parasite-derived cancer therapy and offer novel insights for the evolution of advanced cancer therapeutics. Several studies have demonstrated that parasites offer a variety of strategies for cancer therapy. These include acting as immunotherapeutics such as cancer vaccines, therapeutic antibodies, adjuvants, immunomodulators, oncolytic agents, and NF-κB inhibitors. Additionally, they can be utilized in targeted therapy, gene therapy, and in combination with current cancer treatments to synergistically enhance their effectiveness. A notable strategy is parasites' ability to overcome tumor resistance to chemotherapy, a significant obstacle in cancer therapy. There is still much to explore about parasite-based anti-cancer therapies. With further research and the translation of parasitological discoveries into effective cancer interventions, parasites may hold the key to effectively treat cancer in the near future.

Citer ce document

Eissa, M. M., El-Faham, M. H., & Skhawy, N. E. (2025). Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions. Infectious Agents and Cancer. https://doi.org/10.1186/s13027-025-00679-7

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 28/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations : 1

Téléchargements : 0